Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:01643'
s PB Ratio Range Over the Past 10 Years
Min: 0.35 Med: 0.67 Max: 4.74
Current: 1.24
During the past 9 years, Modern Chinese Medicine Group Co's highest PB Ratio was 4.74. The lowest was 0.35. And the median was 0.67.
HKSE:01643's PB Ratio is ranked better than 68.4% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs HKSE:01643: 1.24
During the past 12 months, Modern Chinese Medicine Group Co's average Book Value Per Share Growth Rate was -11.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -1.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 18.90% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Modern Chinese Medicine Group Co was 83.20% per year. The lowest was -1.00% per year. And the median was 32.30% per year.
Back to Basics: PB Ratio
Modern Chinese Medicine Group Co (HKSE:01643) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Modern Chinese Medicine Group Co PB Ratio Related Terms
Modern Chinese Medicine Group Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Modern Chinese Medicine Group Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modern Chinese Medicine Group Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Modern Chinese Medicine Group Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Modern Chinese Medicine Group Co's PB Ratio falls into.
Modern Chinese Medicine Group Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Modern Chinese Medicine Group Co (HKSE:01643) has a PB Ratio of 1.23 as of Jul. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Modern Chinese Medicine Group Co and its competitors. This is 84% above median its historical median of 0.67. Over the past decade, Modern Chinese Medicine Group Co's PB Ratio has ranged from 0.35 to 4.74. According to the industry distribution chart, Modern Chinese Medicine Group Co ranks #291 out of 921 companies in the Drug Manufacturers industry, placing it in the top 31.6%.
Is Modern Chinese Medicine Group Co's PB Ratio too high?
Modern Chinese Medicine Group Co's current PB Ratio of 1.23 is 84% above median its 10-year median of 0.67. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 4.74. The Drug Manufacturers industry median PB Ratio is 1.90. Modern Chinese Medicine Group Co's value of 1.23 is 35.3% below this industry median. Based on the distribution chart, Modern Chinese Medicine Group Co ranks #291 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Modern Chinese Medicine Group Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Modern Chinese Medicine Group Co's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Modern Chinese Medicine Group Co ranks #291 out of 921 companies for PB Ratio. This puts Modern Chinese Medicine Group Co in the upper half of its industry. The industry median PB Ratio is 1.90. Modern Chinese Medicine Group Co's value of 1.23 is 35.3% below this benchmark. Historically, Modern Chinese Medicine Group Co's own PB Ratio has ranged from 0.35 to 4.74 over the past decade. While the company's 10-year median is 0.67 vs. the industry median of 1.90, Modern Chinese Medicine Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Modern Chinese Medicine Group Co's current PB Ratio of 1.23 is 35.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Modern Chinese Medicine Group Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modern Chinese Medicine Group Co's current PB Ratio is 1.23, which is 84% above median its own 10-year median of 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modern Chinese Medicine Group Co stock overvalued right now?
Based on GuruFocus' analysis, Modern Chinese Medicine Group Co (HKSE:01643) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.16, compared to a current price of HK$0.94 — trading 487.5% above its estimated fair value. The current PB Ratio is 1.23, which is 84% above median its 10-year median of 0.67 and 35.3% below the Drug Manufacturers industry median of 1.90. Modern Chinese Medicine Group Co's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Modern Chinese Medicine Group Co (HKSE:01643), the current PB Ratio is 1.23 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Modern Chinese Medicine Group Co (HKSE:01643) Overvalued in 2026?
Based on GuruFocus' analysis, Modern Chinese Medicine Group Co stock appears to be overvalued.
The current stock price of HK$0.94 is trading 487.5% above its estimated GF Value™ of HK$0.16.
GuruFocus considers Modern Chinese Medicine Group Co to be Significantly Overvalued.
Key valuation signals for HKSE:01643:
PB Ratio: 1.23 (84% above median its 10-year median of 0.67)
GF Value™: HK$0.16 vs. price of HK$0.94 (487.5% above fair value)
Industry Position: 35.3% below the Drug Manufacturers median (#291 of 921)
No single metric tells the full story. See the HKSE:01643 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Modern Chinese Medicine Group Co Business Description
Modern Chinese Medicine Group Co Ltd is engaged in the production of Proprietary Chinese Medicines. It offers both OTC and prescribed medicines intended for use by the Middle-aged and the Elderly in the PRC. Its products include liver protection tablets, Shanmei capsules, Qi and blood supplement pills, and Xiaohuoluo pills, among others. Geographically, the company derives its key revenue from the People's Republic of China.
53GF Score
Get the complete analysis for HKSE:01643
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01643 has been successfully added to your 
